NCT05571163View on ClinicalTrials.gov

A Study to Evaluate the Relative Bioavailability of AMG 510 Administered as Tablets and as a Water Dispersion in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

March 6, 2020

Primary Completion Date

June 14, 2020

Study Completion Date

June 14, 2020

Conditions
Healthy Participants
Interventions
DRUG

AMG 510

Tablets

Trial Locations (1)

75247

Covance Clinical Research Unit, Inc 1341 W Mockingbird Ln, Ste 200E, Dallas

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY